Immunosuppression in solid organ transplant patients is attributed to iatrogenic medications to prevent organ rejection, including a combination of antiproliferative agents, calcineurin inhibitors, corticosteroids, mammalian target of rapamycin (mTOR) inhibitors, and T cell co-stimulation blockers; transplant patients remain on a maintenance regimen of immunosuppressive medication, following initial induction therapy, for many years, thus increasing the risk of several secondary diseases, including malignancies [12]. Here, MTOR is linked to cancer.